FDAnews Announces — Brexit and Life Sciences Companies Webinar, May 31, 2017

Share Article

International drug and device business is at a crossroads known as ‘Brexit’, the imminent departure of the United Kingdom (U.K.) from the European Union (EU). FDAnews has invited Michael Burke Esq., an expert on drugs and devices as well as a specialist in cross-border international trade, to share his insights.

Brexit and Life Sciences Companies
**An FDAnews Webinar**
May 31, 2017 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/brexitlscompanies                        

When Britain exits the EU, what happens?

Will the EMA stay in London? What happens with the Unified Patient Court?

The Brexit is about to happen. Manufacturers need answers before that happens.

Get a look into the Brexit future. Mark the calendar for a standout webinar presentation on Wednesday, May 31 with a lawyer who specializes in the global drug and device business.

Michael Burke Esq., Partner, Arnall Golden Gregory LLP is his firm’s in-house expert on drugs and devices as well as a specialist in cross-border international trade. His particular focus, Ireland, is the one remaining English-speaking nation in a post-Brexit EU.

Mr. Burke counsels transnational drug and device clients on trade issues including anti-boycott regulations, export controls, economic sanctions and the Foreign Corrupt Practices Act, to mention just a few. In 90 intense minutes, he’ll answer the following questions and more:

  •     How might Brexit affect my operation, both short- and long-term?
  •     Should manufacturers consider moving operations into or out of the U.K?
  •     What are the advantages and disadvantages of operating in Ireland?
  •     How will marketing authorization in both the EU and U.K. be affected?

Meet the Presenter:
Michael Burke Esq., Partner, Arnall Golden Gregory LLP
Washington lawyer Michael Burke has dual qualifications as a guide to the post-Brexit world: He is his firm’s in-house expert on drugs and devices; and a specialist in cross-border international trade. His particular focus, Ireland, is the one remaining English-speaking nation in a post-Brexit EU. Mr. Burke counsels transnational clients on anti-boycott regulations, export controls, economic sanctions and the Foreign Corrupt Practices Act; and represents them before the Justice Dept., Treasury Office of Foreign Assets Control, State Dept. Office of Defense Trade Controls and Commerce Dept. Bureau of Industry and Security. He is author of the Irish Export Insights blog, https://irishexportinsights.com/, and co-editor and co-author of The Corporate Counsel’s Guide to Doing Business in China (Thomson Reuters).

Who Will Benefit:
This top-level Web presentation is aimed at senior officials: President, Vice President, CEO/COO/CFO as well as executives with responsibilities in:

  •     Operations
  •     Supply Management
  •     Regulatory Affairs
  •     Quality Assurance

Webinar Details:
Brexit and Life Sciences Companies
**An FDAnews Webinar**
May 31, 2017 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/brexitlscompanies                    

Tuition:
$287 per site

Easy Ways to Register:
Online:     http://www.fdanews.com/brexitlscompanies                                                                
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Butler
FDANEWS
+1 (703) 538-7665
Email >
FDAnews
Like >
Visit website